Research professionals are encouraged to use the contact information on the "Our Team" page of this site to get in touch with members of the NCPC team, or email us at ncpc@northwestern.edu for more information about chemoprevention trials.
Information regarding previous publications and findings can be found in the "Completed Trials" section of our website.
Do you have non-alcoholic fatty liver disease (NAFLD)?
NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD is becoming more common and is found in about 25% of the general population worldwide. People with NAFLD have a higher-than-average risk of chronic liver disease, cirrhosis, and one kind of liver cancer, hepatocellular carcinoma (HCC). HCC is increasing more rapidly than any other cancer in the United States, due mainly to an increase in NAFLD in the general population.
The usual approach for patients diagnosed with NAFLD is to be followed closely by their doctor to watch for worsening of liver disease, which could include the development of cirrhosis and cancer. Imaging studies – tests that take pictures of your liver – and blood tests are done every 6-12 months. Weight loss, healthy diet and exercise are the recommended treatments for non-alcoholic fatty liver diseases. Currently, there is no Food and Drug Administration (FDA) approval for any drugs to treat NAFLD.
Role of lisinopril in preventing the progression of non-alcoholic fatty liver disease
Principal Investigator:
This study will test the effects of lisinopril on people’s risk of developing hepatocellular carcinoma (HCC). Lisinopril is a medication that has been commonly used to treat high blood pressure since 1987 in the U.S. Participants in this study will receive 10 mg of lisinopril orally once daily for up to 24 weeks, in addition to their standard of care. This will allow researchers to see if participants taking lisinopril show changes in their liver, which may indicate a lower risk of developing cancer. This study is looking for volunteers who are 18 years of age or older and have NAFLD. We will enroll 40 participants.
You may be eligible if:
• You have a higher-than-average risk of developing liver cancer due to your diagnosis of NAFLD
• You have advanced fibrosis (scarring)
If you think you may be eligible, you can contact a study coordinator
CEDARS-SINAI MEDICAL CENTER – Manaf Alsudaney: (310) 967-7454, manaf.alsudaney@cshs.org – Los Angeles, California
DUKE UNIVERSITY – Magdi Elgasim: (919) 684-9019, magdi.elgasim@duke.edu – Durham, North Carolina
MOUNT SINAI HEALTH SYSTEM – Hannah Gulko: (212) 824-7582, hannah.gulko@mssm.edu– New York, New York
MAYO CLINIC – Mia Mahmoud: (507) 284-0361, Mahmoud.Mia@mayo.edu– Rochester, Minnesota
More Information: https://clinicaltrials.gov/ct2/show/NCT04550481
Additional Resources
Study Brochure
